Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROAIR HFA vs VOSOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
Terminal elimination half-life: 3.8 to 5 hours; clinically, this supports a dosing interval of every 4-6 hours as needed for symptom relief.
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Primarily metabolized by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfation; not metabolized by CYP450 enzymes.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Renal: approximately 72% as unchanged drug and metabolites; fecal: approximately 10%; biliary: minimal.
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
Approximately 94% bound to human serum albumin.
90–95%, primarily to albumin.
Vd: 1.9 to 2.7 L/kg; this large Vd indicates extensive distribution into tissues, including lung tissue.
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Inhalation: approximately 10-20% of the administered dose reaches the lungs; the remainder is swallowed and undergoes first-pass metabolism resulting in negligible oral bioavailability.
Otic: 80–90% (local absorption with minimal systemic).
No dosage adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
No dosage adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment.
Children 4-11 years: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise. Children <4 years: Safety and efficacy not established.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased sensitivity to beta-agonists.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
Not applicable; no black box warning.
None
Paradoxical bronchospasm may occur,Cardiovascular effects: increased heart rate, blood pressure, or ECG changes,Immediate hypersensitivity reactions,Potentially severe hypokalemia,May exacerbate diabetes and ketoacidosis
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Hypersensitivity to albuterol or any component of the formulation
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
No significant food interactions. Avoid caffeine and stimulants as they may increase cardiovascular side effects (tachycardia, palpitations). No dietary restrictions required.
No known food interactions. Alcohol consumption is not restricted.
FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at doses 0.4-1.2 times the maximum human daily inhalation dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk. For trimester-specific risks: first trimester: potential for orofacial clefts and limb defects; second/third trimesters: risk of maternal tachycardia and hypoglycemia in neonate; labor inhibition near term; possible neonatal transient hypoglycemia.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Albuterol is excreted into human breast milk in small amounts (M/P ratio not established). No reported adverse effects in nursing infants. Use with caution in lactating women; benefit of breastfeeding should outweigh potential risk to infant. Monitor infant for signs of beta-adrenergic stimulation (tachycardia, irritability).
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
No specific dose adjustment required; however, pharmacokinetic changes in pregnancy (increased volume of distribution, increased clearance) may theoretically require dose frequency adjustment. Use the lowest effective dose and monitor clinical response. No dose adjustment needed based on current evidence.
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
Primarily a rescue inhaler for acute asthma exacerbations. Not for maintenance therapy. Shake well before each use. Prime with 3 test sprays when new or not used for >2 weeks. Use spacer device to improve lung deposition and reduce oropharyngeal side effects. Monitor for paradoxical bronchospasm. Tachycardia and hypokalemia can occur with overuse. Replace canister after 200 actuations.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
Use only as needed for shortness of breath, wheezing, or chest tightness.,Do not use more frequently than prescribed; overuse can lead to serious side effects.,Shake the inhaler vigorously for 5 seconds before each spray.,Prime the inhaler by releasing 3 test sprays into the air before first use or if not used for more than 2 weeks.,Use a spacer device if prescribed to improve medication delivery to the lungs.,Rinse mouth with water after each use to prevent thrush (oral fungal infection).,Seek immediate medical help if symptoms worsen or if you need more than 2 puffs per week for relief.,Store at room temperature away from moisture and heat; do not freeze.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROAIR HFA vs VOSOL HC, answered by our medical review team.
PROAIR HFA is a Beta-2 Agonist Bronchodilator that works by Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROAIR HFA and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROAIR HFA is: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROAIR HFA and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROAIR HFA is classified as Category C. FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at dos. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.